# Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects

> **NCT02422446** · PHASE3 · TERMINATED · sponsor: **Brigham and Women's Hospital** · enrollment: 2 (actual)

## Conditions studied

- Type 2 Diabetes
- Coronary Artery Disease

## Interventions

- **DRUG:** Icosapent ethyl

## Key facts

- **NCT ID:** NCT02422446
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2017-03-01
- **Final completion:** 2017-03-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Difficulty enrolling patients with elevated triglycerides under statin treatment
- **Last updated:** 2022-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02422446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02422446, "Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02422446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*